Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 1998; 80(04): 707-709
DOI: 10.1055/s-0037-1615450
DOI: 10.1055/s-0037-1615450
Letters to the Editor
Association of Red-blood Methylfolate but not Plasma Folate with C677T MTHFR Polymorphism in Venous Thromboembolic Disease
Authors
Further Information
Publication History
Received
06 March 1998
Accepted after revision
09 June 1998
Publication Date:
08 December 2017 (online)
-
References
- 1 Moghadasian MH, McManus BM, Frohlich JJ. Homocysteine and coronary artery disease. Clinical evidence and genetic and metabolic background. Arch Intern Med 1997; 157: 2299-308.
- 2 Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM. et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-81.
- 3 Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 4: 1080-3.
- 4 Fermo I, D’Angelo SV, Paroni R, Mazzola G, Calori G, D’Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995; 123: 747-53.
- 5 den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH. Hyper-homocysteinemia as a risk factor for deep-vein thrombosis. N Eng J Med 1996; 334: 759-62.
- 6 Jacques PF, Bostom AG, Williams RR, Curtis Ellison R, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
- 7 Pancharuniti N, Lewis CA, Sauerlich HE, Perkins LL, Go RCP, Alvarez JO. Plasma homocyst(e)ine, folate and vitamin B12 concentrations and the risk for early-onset coronary artery disease. Am J Clin Nutr 1994; 59: 940-8.
- 8 Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 1996; 275: 1893-96.
- 9 Zittoun J, Tonelli AP, J Marquet de Jialluly E, Hancock C, Yacobi A, Johnson JB. Pharmacokinetic comparison of leucovorin and levoleucovorin. Eur J Clin Pharmacol 1993; 44: 69-73.
- 10 Faure-Delanef L, Quéré I, Chassé JF, Zittoun J, Guerassimenko O, Lesaulnier M, Bellet H, Kamoun P, and Cohen D. Methylenetetrahydrofolate reductase thermolabile variant and human longevity. Am J Hum Genet 1997; 60: 999-1001.
- 11 Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow R, Willett WC, Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardial infarction in US Physicians. Circulation 1996; 94: 2410-6.
- 12 Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case-control study. Circulation 1996; 94: 1812-4.
- 13 Molloy AM, Daly S, Mills J, Kirke PN, Whitehead AS, Ramsbottom D, Conley MR, Weir DG, Scott JM. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates : implications for folate intake recommendations. Lancet 1997; 349: 1591-3.